Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: A mature follow-up report
Annals of OncologyPublished 1 May 1999Open access
Sebastian Fetscher, Wolfram Brugger, R. Engelhardt, Lothar Kanz, J. Hasse, H Frommhold
Citations24
SJR quartileQ1
SJR score19.07
SNIP10.48
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The activity of VIP-E SDC and VIC-E HDC is not superior to that of established protocols in the treatment of NSCLC, and less aggressive regimens should be preferred for most patients.
Abstract
Despite high response rates, survival after VIP-E SDC and VIC-E HDC in patients with ED SCLC is not superior to that achieved with less toxic traditional regimens. The high five-year survival rates achieved with these protocols in LD SCLC probably reflect both patient selection (high proportion of patients with prior surgical resection) and the high activity of our chemotherapy regimen in combination with radiotherapy. A study comparing protocols using simultaneous radiation therapy and chemotherapy, and other dose-escalated forms of SDC with HDC is needed to further define the role of this treatment modality in SCLC. Given the high rate of secondary malignancies observed in patients in CR > 2 years in our study, close follow-up and early treatment of these neoplasms may contribute to maintaining overall survival in patients with SCLC.
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
Springer series in statisticsNonparametric Estimation from Incomplete Observations
45,533 Citations1992Edward L. Kaplan, Paul Meier
Journal of the American Statistical AssociationNonparametric Estimation from Incomplete Observations
39,052 Citations1958Edward L. Kaplan, Paul Meier
New England Journal of MedicineTwice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide
1,477 Citations1999Andrew T. Turrisi, KyungMann Kim +7 more
Four cycles of cisplatin plus etoposide and a course of radiotherapy beginning with cycle 1 of the chemotherapy resulted in overall two- and five-year survival rates of 44 percent and 23 percent, a considerable improvement in survival rates over previous results.
New England Journal of MedicineA Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung Cancer
1,264 Citations1994R. Rosell, José Gómez‐Codina +13 more
Preoperative chemotherapy increases the median survival in patients with non-small-cell lung cancer, and the prevalence of mutated K-ras oncogenes was 15 percent among the patients receiving preoperative chemotherapy and 42 percent among those treated with surgery alone.
BloodMalignant neoplasms following bone marrow transplantation
415 Citations1996Shivank Bhatia, NK Ramsay +7 more
Recipients of bone marrow transplant (BMT) are at an increased risk of later malignancy, which may add significant morbidity and mortality to the transplant process.
CHEST JournalA Prospective Randomized Trial to Determine the Benefit of Surgical Resection of Residual Disease Following Response of Small Cell Lung Cancer to Combination Chemotherapy
348 Citations1994Thomas E. Lad, Steven Piantadosi +4 more
The results of this trial do not support the addition of pulmonary resection to the multimodality treatment of small cell lung cancer.
Journal of Clinical OncologyLong-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients.
284 Citations1995Ulrik Lassen, Kell Østerlind +4 more
Long-term survival can be achieved for both stages of SCLC, but without any change in survival rates over the last decade, as well as long-term prognostic factors.
Journal of Clinical OncologyProspective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
251 Citations1994Daniel C. Ihde, James L. Mulshine +8 more
No therapeutic benefits resulted from increasing planned doses by 67% for the first two cycles of EP in patients with extensive-stage SCLC, and higher doses were associated with substantially worse toxicities.
Journal of Clinical OncologyPhase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
198 Citations1998Noah C. Choi, James E. Herndon +7 more
The maximum-tolerated dose (MTD) of radiation (RT) in both standard daily and hyperfractionated-accelerated (HA) twice-daily RT schedules in concurrent chemoradiation was determined to be at least 70 Gy in 35 fractions over 7 weeks.
PubMedChronic lymphocytic leukemia: staging and prognostic factors.
196 Citations1998James A. Zwiebel, Bruce D. Cheson +6 more
A phase II trial including high-dose chemotherapy and peripheral blood progenitor cell transplantation (PBPCT) as part of an early intensification strategy after two cycles of induction therapy demonstrates that a multimodality treatment including early high- dose chemotherapy with PBPCT may lead to a prolonged disease-free survival in the majority of patients.
Journal of Clinical OncologyDose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung.
134 Citations1991Richard Klasa, Nevin Murray +1 more
It is concluded that DI-outcome correlations are not consistent for these chemotherapy regimens in SCCL.
Journal of Clinical OncologyCan cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
129 Citations1995Penella J. Woll, Jackie Hodgetts +4 more
The G-CSF group received a significantly higher dose-intensity than the control group, with the greatest difference in the first three cycles, and had a better 2-year survival rate than controls.
Journal of Clinical OncologyPatients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
126 Citations1996Bruce E. Johnson, J D Bridges +14 more
This combined modality regimen for patients with limited-stage small-cell lung cancer results in a 2-year survival rate of 43%, but the principal cause of death in these patients is still relapse of the original cancer.
Journal of Clinical OncologyHigh-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma.
85 Citations1986Gary Spitzer, Peter Farha +8 more
In conclusion, intensification with high-dose chemotherapy can increase the CR rate, and this approach is most likely to show long-term benefits in patients with minimal disease (CR) at the beginning of intensification therapy.
Cancer Chemotherapy and PharmacologyHigh-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung carcinoma
75 Citations1985Ian E. Smith, B D Evans +5 more
High-dose cyclophosphamide after conventional chemotherapy is feasible and achieves a high response rate, but it does not appear to be associated with significant survival benefit either overall or in patient subgroup.
Journal of Clinical OncologyRandomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party.
72 Citations1996Jean‐Paul Sculier, M Paesmans +11 more
It is concluded that maintenance chemotherapy in responding patients is beneficial in SCLC in a multi-variate analysis that took into account disease extent, maintenance therapy, Karnofsky performance status (PS), and absolute dose-intensity (ADI) of anthracycline given during induction were found to be independent positive predictors of survival.
Journal of Clinical OncologyMulticyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood.
71 Citations1995Ruth Pettengell, Penella J. Woll +3 more
The dose-intensity of ICE chemotherapy can be doubled by reinfusing hematopoietic progenitors collected by leukapheresis or venesection and stored at 4 degrees C.
Journal of Clinical OncologyLate intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer.
71 Citations1986Daniel C. Ihde, A B Deisseroth +8 more
It is concluded that the late intensive combined modality therapy (LICMRX) given in this study can be administered to only a minority of extensive-stage SCLC patients and is very unlikely to yield substantial improvement in the fraction of 2-year survivors.
CancerCarboplatin, etoposide, and accelerated hyperfractionated radiotherapy for elderly patients with limited small cell lung carcinoma
68 Citations1998Branislav Jeremić, Yuta Shibamoto +2 more
A short term combination regimen consisting of carboplatin and etoposide with accelerated hyperfractionated radiotherapy for elderly patients with limited small cell lung carcinoma with palliative intent is employed.
Journal of Clinical OncologyCarboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer.
61 Citations1990Ian E. Smith, Timothy Perren +5 more
Thirty-two previously untreated, fit patients with small-cell lung carcinoma (SCLC) were treated with an intensive combination chemotherapy regimen, with the aim of prolonging survival, as follows.
The American Journal of MedicineNon-small-cell lung cancer. Major cause of late mortality in patients with small cell lung cancer
60 Citations1986Bruce E. Johnson, Daniel C. Ihde +8 more
In this study, the risk of development of non-small-cell lung cancer after two years of disease-free survival following small cell lung cancer is 4.4 percent per person-year, approximately 10 times higher than the rate previously determined in screening studies of men at high risk for lung cancer.
PubMedIntensive chemoradiotherapy with autologous marrow transplantation for small cell carcinoma of the lung.
57 Citations1983Patricia Stewart, CD Buckner +6 more
Ten patients with small cell carcinoma of the lung underwent several courses of conventional therapy and were referred for autologous marrow transplantation, three during a complete response, six during a partial response, and one following no response.
Journal of Clinical OncologyRoutine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model.
55 Citations1998C. Chouaïd, L Bassinet +3 more
Routine use of G-CSF during SCLC chemotherapy is not justified by clinical benefits, improved patient comfort, or economic considerations, and the never strategy was the best choice.
Cancer Chemotherapy and PharmacologyIntensive chemotherapy with autologous bone marrow transplantation for small-cell lung cancer
54 Citations1989R L Souhami, H. Hajichristou +8 more
Although high-dose cyclophosphamide increased the complete response rate, the additional responses were short-lived and the long-term survival does not appear to be different from that in comparably selected cases treated with conventional chemotherapy.
Journal of Clinical OncologyLate intensification in small-cell lung cancer: a phase I study of high doses of cyclophosphamide and etoposide with autologous bone marrow transplantation.
48 Citations1985Jean‐Paul Sculier, Jean Klášterský +1 more
The duration of the responses and the survival rates of the patients were poor, suggesting that late dose intensification in incomplete responders is not superior to the usually reported results obtained with standard regimens for the treatment of SCLC.
CHEST JournalSmall Cell Lung Cancer
44 Citations1995Daniel C. Ihde
New, more effective drugs will be required for any major improvements in the treatment of SCLC, and combined-modality therapy employing chemotherapy and chest irradiation appears to produce excellent cytotoxic effects and is relatively well tolerated in patients with limited disease.
CancerPredictors of survival following relapse or progression of small cell lung cancer. Southwest oncology group study 8605 report and analysis of recurrent disease data base
44 Citations1993Kathy S. Albain, John J. Crowley +6 more
The authors analyzed the SWOG recurrent SCLC data base to assess the value of testing new regimens in previously treated patients and found that there was no independent impact of treatment over favorable prognostic factors.
Annals of OncologyDose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer
41 Citations1997Sebastian Fetscher, Wolfram Brugger +7 more
Compared with traditional protocols such as ACO or carboplatin/etoposide, response rates are slightly improved, while survival is not different, in the LD SCLC subgroup, high-dose chemotherapy improved response rates and survival, however, higher response-rates did not translate into improved survival.
Journal of Clinical OncologyPhase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study.
36 Citations1995Antonio C. Wolff, David S. Ettinger +5 more
ICE with oral etoposide has comparable activity with other regimens in ED SCLC, however, the 2-year survival rate may be higher and ICE with the lower doses of schedule II could be given safely with acceptable toxicity.
Journal of Clinical OncologyEnhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma.
32 Citations1998Vivianne C. G. Tjan‐Heijnen, Bonne Biesma +5 more
G-CSF administration until 48 hours before the next chemotherapy course increases chemotherapy-associated leukocytopenia and thrombocytopene levels and may be of special concern when G- CSF is administered during dose-densified chemotherapy.
CancerA Phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma
30 Citations1998Gregory P. Kalemkerian, Michael R. Jiroutek +4 more
A Phase II trial was designed to determine the effects of the combination of RA, cisplatin, and etoposide in patients with SCLC.
Journal of Clinical OncologyIntensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy.
27 Citations1991J Prendiville, John Radford +5 more
Forty patients with small-cell lung cancer have been treated with an intensive therapy composed of carboplatin alternating with cisplatin, ifosfamide, and etoposide with vincristine, with a median survival of 14 months with an actual 2-year survival of 30% and a minimum follow-up of 28 months.
Cancer Chemotherapy and PharmacologyDose-intensive therapy in lung cancer
25 Citations1997Anthony Elias
The roles of thoracic radiation dose intensity and purification of stem-cell autografts are being evaluated in ongoing trials and it is hoped that a cooperative phase III trial testing the concept of dose intensification will begin soon.
RadiologyLimited-stage small cell lung cancer: local failure after chemotherapy and radiation therapy.
24 Citations1998Takuhito Tada, Kazuo Minakuchi +8 more
Patients with N3 limited-stage small cell lung cancer should undergo a separate protocol, and the upper margin should be extended in patients with N2 or N3 disease.
The Annals of Thoracic SurgeryMultimodal therapy of small cell lung cancer in TNM stages I through IIIa
24 Citations1992Ludwig Müller, G Salzer +5 more
Patients with completed multimodal treatment have a 5-year survival rate of 56% regardless of disease stage, and patients with completed chemotherapy, surgery, and radiotherapy with the same 5- year survival rate have the same rate.
Recent results in cancer research/Recent Results in Cancer ResearchIntensive Chemotherapy with Autologous Bone Marrow Transplantation in Small Cell Carcinoma of the Lung
24 Citations1985Peter Harper, R L Souhami
In spite of improvements in response rate with combination chemotherapy, median survival is poor in both limited and extensive disease and the adoption of the strategy of using “non-cross-resistant” chemotherapy has made little impact on these dismal figures.
CancerHigh-dose, multiple-alkylator chemotherapy with autologous bone marrow reinfusion in patients with advanced non-small cell lung cancer
23 Citations1989Stephanie Williams, Jacob D. Bitran +6 more
Since there are substantial toxicities associated with high‐dose chemotherapy and responses of such brief duration, further investigation with these drug combinations is not warranted.
The Annals of Thoracic SurgeryComparison between resected and irradiated small cell lung cancer in patients in stages I through IIIa
22 Citations1992Yukito Ichinose, Nobuyuki Hara +4 more
Surgical resection can be considered a modality of treatment in clinical stage I and the treatment role of surgical resection in clinical stages II and IIIa, even in selected patients, remains unclear.
CHEST JournalThe Role of Thoracic Radiotherapy in the Management of Limited-Stage Small Cell Lung Cancer
21 Citations1997Parvesh Kumar
Thoracic radiation therapy significantly improves both local chest control and survival in the treatment of limited-stage SCLC.
European Journal of CancerRecombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for non-small cell lung cancer
19 Citations1993Kiyoshi Mori, Yoshikuni Saitoh +1 more
In conclusion, the combined administration of rG-CSF enabled shortening of administration schedule of PiV therapy and increasing the dose intensity.
CHEST JournalNew Agents in the Treatment of Small Cell Lung Cancer
17 Citations1998M. Modares Gilani F. Ghaemmaghami, James R. Jett
New agents showing good preliminary single-agent activity in untreated SCLC include paclitaxel, vinorelbine, gemcitabine, topotecan, and teniposide, and studies evaluating response and survival rates of these new agents in combination with agents of known activity are underway.
CancerProphylactic cranial irradiation in limited-stage small cell lung cancer
14 Citations1995Vichaivood Liengswangwong, James A. Bonner +7 more
This study evaluated PCI in patients with LSSCLC who achieved a complete response to initial chemotherapy and recommended prophylactic cranial irradiation for patients with limited‐stage small cell lung cancer.
British Journal of CancerHigh dose combination chemotherapy with ifosfamide, cyclophosphamide or cisplatin, mitomycin C and mustine with autologous bone marrow support in advanced non-small cell lung cancer. A phase I/II study
14 Citations1991SA Gomm, N. Thatcher +5 more
The high dose regimen was associated with a high (74%) response rate, but with an overall median survival of only 6 months, and the regimen has no advantage over conventional doses with the same agents in patients with metastatic NSCLC.
CHEST JournalHigh-Dose Combined Alkylating Agent Therapy With Autologous Stem Cell Support and Chest Radiotherapy for Limited Small-Cell Lung Cancer
12 Citations1993Anthony Elias, Lois Ayash +8 more
This trial used combined alkylating agents with autologous marrow support and chest radiotherapy in patients with limited disease in response to conventional-dose induction chemotherapy, and found patients who achieved complete or near-complete response prior to high-dose therapy enjoyed the best prognosis.
Chest Surgery Clinics of North AmericaTHE ROLE OF CHEMOTHERAPY IN THE TREATMENT OF SMALL CELL LUNG CANCER
12 Citations1997Frances A. Shepherd
Because small cell lung cancer is a systemic malignancy, chemotherapy is the mainstay treatment for patients with all stages of this tumor, and current research is focusing on ways to increase the dose intensity of chemotherapy delivery.
RadiologyLimited-stage small-cell lung cancer: patient survival after combined chemotherapy and radiation therapy with and without treatment protocols.
11 Citations1995Randi A. Schea, Penny Perkins +3 more
There was a highly statistically significant difference in survival outcome in the nonprotocol group versus the protocol group, and differences in chemotherapy-radiation therapy timing and other treatment-related factors may have contributed substantially to the improved survival in the Protocol group.
Cancer Chemotherapy and PharmacologyHigh-dose carboplatin plus paclitaxel with granulocyte colony-stimulating factor and peripheral blood stem-cell support in non-small-cell lung cancer
10 Citations1997Thomas C. Shea
This study will utilize two cycles of high-dose carboplatin and Taxol given at an AUC dose of 18 and a 24-h infusion dose of 250 mg/m2, respectively, with growth factor and stem-cell support to treat stage III NSCLC patients.
CHEST JournalDose-Intensive Therapy for Small Cell Lung Cancer
10 Citations1995Anthony Elias
Evidence for the contribution of dose intensification to response and survival in the treatment of SCLC is reviewed, the adequacy of the clinical trial's design to address these relationships, and suggestions for future directions are suggested.
PubMedDose intensity in small cell lung cancer.
10 Citations1998Nick Thatcher, Siow Ming Lee +5 more
The novel use of peripheral blood progenitor cells contained in whole blood autotransfusions, which allow a marked increase in dose intensity of an ifosfamide/carboplatin/etoposide regimen, could provide a much easier method of delivering dose-intensive chemotherapy than previously available.
CancerLong term results of a phase I/II study of aggressive chemotherapy and sequential upper and lower hemibody radiation for patients with extensive stage small cell lung cancer
9 Citations1995James A. Bonner, Robert T. Eagan +6 more
A Phase I/II study of an aggressive six‐drug chemotherapy regimen followed by the use of sequential hemibody radiation therapy as a possible non‐cross‐resistant systemic treatment for patients with extensive stage small cell lung cancer found it to be feasible and effective.
CHEST JournalDose-Intensive Therapy in Small Cell Lung Cancer
9 Citations1998Anthony Elias
This paper reviews some of the recently completed and activated trials (particularly those developed at the Dana-Farber Cancer Institute) exploring concepts of induction/intensification mode and multicycle dose-intensive approaches.
CHEST JournalThoracic and Cranial Radiotherapy for Limited-Stage Small Cell Lung Cancer
7 Citations1995Elizabeth Healey, Anthony Abner
Based on limited data, delivery of thoracic radiation early in the treatment course may be preferable to delivery later in the course, and the role of prophylactic cranial irradiation (PCI) is controversial and should be individualized.
Lung CancerHigh dose chemotherapy with autologous bone marrow rescue in small cell lung cancer
7 Citations1989Charles B. Wilson, David Pickering +8 more
The data support the conclusion that high dose chemotherapy and autologous bone marrow rescue has a very small role or none at all in the management of patients with extensive or limited stage SCLC.
CancerHigh-dose carmustine and autologous bone marrow reinfusion in the treatment of refractory or relapsed small cell lung carcinoma
6 Citations1991Daniel A. Rushing, William R. Friedenberg +6 more
In the dosage range of 600 to 1000 mg/m2 in heavily pretreated patients, BCNU is not recommended, but additional investigation may be warranted in patients with central nervous system metastases who previously were treated with radiation therapy.
PubMedHigh-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer.
5 Citations1997Mark A. Socinski, Thomas C. Shea
The development of new agents with significant activity against NSCLC as well as new strategies for high-dose therapy have made it possible to examine the potential of dose-intense therapy in this population, and phase II trials will be needed to establish the role of this approach inNSCLC.
CancerThe results of treatment in 100 patients with limited-stage small cell lung cancer
4 Citations1993Xuyi Liu, Xiaokui Li +4 more
In an attempt to improve treatment results of small cell lung cancer (SCLC), combined induction chemotherapy and thoracic and prophylactic brain radiation therapy were administered.
PubMed[High dose chemotherapy with autologous bone marrow rescue for small cell lung cancer].
2 Citations1992Bao Yh
High dose chemotherapy with autologous bone marrow rescue (ABMR) was given to 10 patients with small cell lung cancer and could be expected to improve the result of intensive chemotherapy for limited SCLC.
PubMed[Possible role of autotransplantation in small cel bronchial carcinoma].
1 Citations1995E Tiefengraber, Christian Sebesta +4 more
The majority of treatment results obtained so far do not clearly suggest a superiority of high-dose therapy with autologous transplantation over conventional polychemo/radiotherapy, and it is unknown, whether or not a subgroup of patients with, e.g., "limited disease" and chemosensitive tumor may benefit from ABMT.
PubMed[Dose-effect of chemotherapy in bronchial small-cell cancer].
1 Citations1997de Crevoisier R, le Cesne A +1 more
The effect of a moderate increase in the initial dose of cisplatinum and cyclophosphamide on survival, opens new directions in the therapeutic strategy of SCLC.
Japanese Journal of Clinical OncologyPatient with Extensive Small Cell Lung Cancer Given Moderately Doseintensified Chemotherapy and Peripheral Blood Stem Cell Support
1 Citations1995Eiji Shimizu, Yoichi Takaue +3 more
A 40-year-old man with extensive SCLC involving the lungs and systemic nodes who was initially treated with 6 cycles of an alternating combination regimen of cyclophosphamide, doxorubicin, vincristine, cisplatin and etoposide is described.